Opinion|Videos|February 13, 2025
Clinical and Economic Consequences of Nonadherence to IV Iron
Panelists discuss how nonadherence to IV iron therapy can lead to persistent anemia, worsening symptoms, increased health care utilization and costs, and diminished quality of life, with patients experiencing continued fatigue, reduced work productivity, and increased risk of complications from their underlying conditions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the potential clinical and economic consequences of nonadherence to IV iron therapy?
- How does nonadherence to therapy decrease patient quality of life?
Advertisement
Related to this article
At an AJMC® Stakeholder Interchange in New York, New York, leukemia specialists agreed that menin inhibitors fill a real gap in relapsed/refractory acute myeloid leukemia, but said that slow molecular testing, formulary rules, and thin community infrastructure still determine which patients get them and how fast.
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.
Advertisement
Advertisement
Trending on AJMC
1
Higher Ropeginterferon Alfa-2b Exposure Liked to JAK2 Reductions in ET
2
Medicare Plan Terminations Hit 4.3 Million as Part D Market Shrinks
3
Menin Inhibitors in AML: In NYC, Experts Map the Path From Academic Centers to Community Care
4
Youths With Depression Face Higher Odds of Prescription Drug Misuse
5